Kinga Jamontt

Ms. Kinga Jamontt

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in Life
Verified
Journal Article
Open access
PDF file
AKAgnieszka Julia Kudasiewicz-Kardaszewska
Agnieszka Julia Kudasiewicz-Kardaszewska
MOMałgorzata Anna Ozimek
Małgorzata Anna Ozimek
TUTomasz Urbański
Tomasz Urbański
KJKinga Jamontt
Kinga Jamontt
ATAleksander Tkaczenko
Aleksander Tkaczenko
SCSławomir Jaroslaw Cisiecki
Sławomir Jaroslaw Cisiecki
Purpose: We aimed to present the clinical outcomes of a combined pharmacological and gas-assisted treatment for sub-macular haemorrhage secondary to neovascular age-related macular degeneration (nAMD). Methods: This retrospective case series included ten eyes with sub-macular haemorrhage (SMH) treated between January 2024 and September 2025. All patients received intravitreal alteplase (100 µg) and C3F8 gas, followed by aflibercept (2 mg or 8 mg) within a treat-and-extend regimen. BCVA- and OCT-based anatomical changes were recorded at baseline, 7–14 days, 1 month, 3 months, and 6 months. BCVA changes were analysed using repeated-measures testing. Results: Mean BCVA improved from 0.99 ± 0.21 logMAR at baseline to 0.89 ± 0.20 at 7–14 days, 0.80 ± 0.20 at 1 month, 0.60 ± 0.18 at 3 months, and 0.53 ± 0.20 at 6 months (p < 0.05 for overall change). Eight eyes (80 percent) showed restoration of foveal contour, while two developed foveal atrophy. No major adverse events occurred. Conclusion: Combined intravitreal alteplase and C3F8, followed by aflibercept, may provide favourable short-term visual and anatomical improvement in SMH secondary to nAMD. Early intervention appears beneficial, but larger controlled studies are needed to confirm these findings.

8 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MOMałgorzata Anna Ozimek
Małgorzata Anna Ozimek
PŁPaulina Łazarczyk
Paulina Łazarczyk
KJKinga Jamontt
Kinga Jamontt
TUTomasz Urbański
Tomasz Urbański
AKAgnieszka Julia Kudasiewicz-Kardaszewska
Agnieszka Julia Kudasiewicz-Kardaszewska
Faricimab (Vabysmo, Roche, EU) may improve treatment durability while maintaining functional and anatomical outcomes in neovascular age-related macular degeneration (nAMD). This single-centre retrospective study evaluated 52 eyes of 49 refractory nAMD patients switched from ranibizumab, aflibercept 2 mg, or brolucizumab to faricimab. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), injection intervals, optical coherent tomography (OCT) fluid, and adverse events were assessed at baseline and last follow-up. Mean age was 78.8 years. Before switching, patients had received a mean of 21.85 injections over 996 days, and 77.4% were short responders, with a mean treatment interval of 6.3 weeks. After a mean 466 days of faricimab treatment, BCVA remained stable, changing from 0.389 to 0.378 logMAR (mean change −0.012 logMAR; p = 0.509). BCVA improved in 19.2%, remained stable in 67.3%, and worsened in 13.5% of eyes. CRT decreased significantly from 257.8 to 224.8 μm (mean change −32.9 μm; p = 0.00005). The mean injection interval increased to 8.0 weeks, reaching 8.42 weeks among eyes continuing faricimab. Thirteen eyes (25%) required switching to aflibercept 8 mg because of recurrent fluid or OCT worsening. No endophthalmitis or severe intraocular inflammation occurred. Faricimab maintained vision, improved macular anatomy, and reduced treatment burden, although some refractory eyes required further treatment escalation.

13 July 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AMAnna Matuszek
Anna Matuszek
ESEwa Siedy-Florek
Ewa Siedy-Florek
ZSZofia Stawowy
Zofia Stawowy
MSMaja Strzeszyna
Maja Strzeszyna
KSKatarzyna Szlachetka
Katarzyna Szlachetka
MMMagdalena Ewa Matlakiewcz
Magdalena Ewa Matlakiewcz
Asthma is a chronic inflammatory airway disease that is marked by variable airflow limitation and hyperresponsiveness of the airways. Although pharmacologic management remains the mainstay of asthma therapy, physical exercise and other non-pharmacologic treatments are increasingly found to have an adjunctive function in the disease control. The present review collates available information on the role of physical training as an add-on therapy in the treatment of asthma. It focuses on how proper regular exercise can enhance pulmonary function, reduce symptom burden, and improve quality of life. Particular attention is given to the swimming environment and its multidirectional interaction with asthma, such that exposure to chlorinated by-products can enhance airway inflammation even as the activity has beneficial physiological effects. The article also addresses the physiological mechanisms of exercise-induced asthma (EIA), recommended exercise modalities and intensities, and assessment of physical activity in asthmatic patients. The overall results point to the necessity of individualized, multidisciplinary management encompassing both medical and lifestyle intervention in the treatment of asthma.

31 March 2026 in Cureus
Verified
Journal Article
Open access
KJKinga Jamontt
Kinga Jamontt
MOMalgorzata A Ozimek
Malgorzata A Ozimek
MNMartyna Nowak
Martyna Nowak
BRBarbara Roguska
Barbara Roguska
KSKatarzyna Szlachetka
Katarzyna Szlachetka
AKAgnieszka Kudasiewicz-Kardaszewska
Agnieszka Kudasiewicz-Kardaszewska
Postoperative inflammation after phacovitrectomy is typically mild, occurs early, and resolves with corticosteroid therapy. Delayed or recurrent uveitis following an initially uneventful postoperative course is uncommon and should prompt evaluation for non-infectious inflammatory causes, including underlying systemic disease. A 71-year-old man developed severe intraocular inflammation shortly after discontinuation of postoperative corticosteroids following uncomplicated phacovitrectomy. The early postoperative course was unremarkable. Repeated and detailed history taking revealed previously undisclosed ankylosing spondylitis with HLA-B27 positivity and a remote episode of iritis. The inflammatory flare was attributed to immune reactivation triggered by surgical stress and steroid withdrawal, necessitating intensive topical and systemic corticosteroid therapy. This case highlights the importance of thorough and repeated medical history assessment in patients with atypical postoperative inflammation. HLA-B27-associated disease should be considered in cases of delayed uveitis following intraocular surgery, as early recognition may influence perioperative management and reduce the risk of recurrent, vision-threatening complications.

28 February 2026 in Archiv Euromedica
Verified
Journal Article
Closed access
WJWiktoria Janik
Wiktoria Janik
MNMartyna Nowak
Martyna Nowak
BRBarbara Roguska
Barbara Roguska
KSKatarzyna Szlachetka
Katarzyna Szlachetka
JCJulia Chołda
Julia Chołda
MLMałgorzata Landowska
Małgorzata Landowska
Introduction Laryngectomy is a surgical intervention that involves the partial or complete excision of the larynx, which is the primary organ responsible for phonation and airway protection. The most common indications for laryngectomy are malignancies of the larynx or severe trauma resulting in extensive damage to the larynx. The surgical procedure can be performed as a partial laryngectomy, which involves the removal of a portion of the larynx, or as a total laryngectomy, which requires the complete removal of the larynx, including the vocal folds, hyoid bone, epiglottis, thyroid and cricoid cartilage, and several rings of tracheal cartilage. This surgical intervention results in the separation of the upper airway from the oral cavity, nasopharynx, and esophagus, requiring the establishment of an alternative means for respiration and speech production. The management of patients who undergo laryngectomy requires a multidisciplinary approach, including the involvement of speech therapist and psychologists, among other healthcare professionals, to optimize the rehabilitation process and improve patient outcomes. Case presentation A 66-year-old male patient with a 30-year history of cigarette smoking was admitted to the ear, nose, and throat (ENT) clinic for complaints of hoarseness and dysphagia that had been present for several months. On examination, the patient's throat was unchanged, and there was no purulent discharge from the nose. The patient was diagnosed with laryngeal carcinoma, stage T3N1M0. Conclusions Total laryngectomy is a highly effective treatment option for advanced stage laryngeal cancer, with 5-year survival rates ranging from 53% to 86%. Patients who undergo total laryngectomy and receive a voice prosthesis and voice rehabilitation with a speech therapist report better voice quality and overall quality of life, which can help to reduce the risk of depression and anxiety following surgery.